GC
MRNA icon

Guggenheim Capital’s Moderna MRNA Stock Holding History

Guggenheim Capital’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.87M Sell
55,313
-774
-1% -$40K 0.02% 522
2026
Q1 		$2.85M Sell
56,087
-9,238
-14% -$431K 0.02% 599
2025
Q4 		$1.93M Buy
65,325
+2,598
+4% +$70.6K 0.01% 685
2025
Q3 		$1.62M Buy
62,727
+1,677
+3% +$46.8K 0.01% 745
2025
Q2 		$1.68M Buy
61,050
+6,022
+11% +$159K 0.01% 703
2025
Q1 		$1.56M Buy
55,028
+1,395
+3% +$49.5K 0.01% 712
2024
Q4 		$2.23M Sell
53,633
-91,055
-63% -$4.35M 0.02% 619
2024
Q3 		$9.67M Buy
144,688
+13,157
+10% +$1.21M 0.07% 320
2024
Q2 		$15.6M Sell
131,531
-7,188
-5% -$910K 0.11% 178
2024
Q1 		$14.8M Sell
138,719
-20,790
-13% -$2.1M 0.1% 196
2023
Q4 		$15.9M Buy
159,509
+12,632
+9% +$1.06M 0.12% 178
2023
Q3 		$15.2M Buy
146,877
+5,122
+4% +$571K 0.13% 172
2023
Q2 		$17.2M Buy
141,755
+14,669
+12% +$1.96M 0.14% 149
2023
Q1 		$19.5M Buy
127,086
+6,056
+5% +$999K 0.16% 128
2022
Q4 		$21.7M Sell
121,030
-1,368
-1% -$224K 0.19% 113
2022
Q3 		$14.5M Sell
122,398
-11,762
-9% -$1.78M 0.13% 178
2022
Q2 		$19.2M Sell
134,160
-3,540
-3% -$506K 0.15% 152
2022
Q1 		$23.7M Sell
137,700
-29,589
-18% -$4.98M 0.14% 160
2021
Q4 		$42.5M Buy
167,289
+41,269
+33% +$12.1M 0.22% 85
2021
Q3 		$48.5M Sell
126,020
-4,150
-3% -$1.53M 0.29% 56
2021
Q2 		$30.6M Buy
130,170
+2,994
+2% +$535K 0.18% 98
2021
Q1 		$16.7M Sell
127,176
-20,184
-14% -$2.92M 0.11% 210
2020
Q4 		$15.4M Sell
147,360
-26,563
-15% -$2.69M 0.1% 205
2020
Q3 		$12.3M Buy
173,923
+50,270
+41% +$3.5M 0.09% 224
2020
Q2 		$7.94M Buy
+123,653
New +$6.77M 0.06% 347

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Guggenheim Capital's MRNA Position: Q2 2026 in Review

Guggenheim Capital reduced its Moderna (MRNA) stake by 1.4% in Q2 2026, selling an estimated $40K and leaving 55,313 shares worth $3.87M. The position accounts for 0.02% of the portfolio, ranked #522.

Guggenheim Capital first reported a position in MRNA in Q2 2020 and has held it in 25 quarters since. The position peaked at $48.5M in Q3 2021. 780 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Guggenheim Capital held 55,313 shares of Moderna worth $3.87M as of Q2 2026.
  • Guggenheim Capital sold 774 Moderna shares in Q2 2026, an estimated $40K.
  • Moderna made up 0.02% of Guggenheim Capital's portfolio in Q2 2026, its #522 holding.
  • Guggenheim Capital first reported a position in Moderna in Q2 2020 and has held it in 25 quarters since.
  • Guggenheim Capital's Moderna position peaked at $48.5M in Q3 2021.
  • 780 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Guggenheim Capital's 13F filing for Q2 2026, filed 12 Aug 2026.